Sarepta Therapeutics, Inc.
https://www.sarepta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sarepta Therapeutics, Inc.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Emergex Goes To Battle Against ‘The Nasties’
Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?
BioNTech and the UK government's alliance to bring personalized cancer immunotherapy to patients is making progress, but the National Health Service has to show it can deliver on clinical trials recruitment.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- AVI BioPharma, Inc.
- Ercole Biotech, Inc.
- Myonexus Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice